SynthesisSystematic reviews2026
Association between 6:2 chlorinated polyfluoroalkyl ether sulfonic acid exposure and glucolipid metabolism in Chinese adults: a meta-analysis.
Synthesis in Systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn China, 6:2 chlorinated polyfluoroalkyl ether sulfonic acid (6:2 Cl-PFESA), commercially designated as F-53B, has been predominantly implemented as the perfluorooctane sulfonate (PFOS) substitute, with its 8:2 derivative showing negligible relevance to population exposure. Previous studies have found that 6:2 Cl-PFESA is closely related to dyslipidemia and disrupted glucose homeostasis, though results remain inconsistent.
methodsOur study aimed to separately investigate the potential associations of 6:2 and 8:2 Cl-PFESA with glucolipid metabolism indicators in Chinese adults. A comprehensive systematic literature search was conducted across three major databases-PubMed, Embase, and Web of Science-by 23 September 2024. Random effects models were employed to estimate changes in blood lipid and glucose parameters with one interquartile range (IQR) increment in mean blood concentration of 6:2 and 8:2 Cl-PFESA. Subgroup analyses were performed based on different populations and types of diabetes. A Bayesian random-effects meta-regression model was conducted to attribute differences apparent between individual empirical estimates to mean 6:2 Cl-PFESA concentration.
resultsThe analysis included 17 publications with more than 17, 000 participants. Meta-analyses revealed that each IQR increase of 6:2 Cl-PFESA exhibited significantly positive correlations with a 3.90 mg/dl change in total cholesterol (TC) (95% CI: 1.97, 5.83), and a 2.94 mg/dl change in low-density lipoprotein cholesterol (LDL-C) (95% CI: 1.47, 4.41) among the general adult population. The odds ratio (OR) for gestational diabetes mellitus (GDM) among pregnant women exposed to 6:2 Cl-PFESA was 1.61 (95% CI: 1.15, 2.27). Studies on 8:2 Cl-PFESA were insufficient.
conclusionThe results demonstrated that 6:2 Cl-PFESA was significantly related to TC, LDL-C, as well as the risk of GDM. These findings challenge the current industrial designation of 6:2 Cl-PFESA as a safer alternative, necessitating explicit regulatory re-evaluation pending comprehensive mechanistic evidence that elucidates its biological interactions. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024581843.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.